Formation Bio, Inc.

Quick facts

Phase 2 pipeline

• ASN008 · Diabetes
  ASN008 is a small molecule that targets the SGLT1 transporter.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Formation Bio, Inc. portfolio CI brief
• Formation Bio, Inc. pipeline updates RSS